次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

インスリン製剤の世界市場:タイプ別2020年予測と動向

Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020

出版元:MarketsandMarkets(米国)LinkIcon出版元について
発行年:2016年1月
定価 Single User License(1名様ライセンス)US$4,650(米国ドル)/Multi User License(5名様)$5,650 /Corporate User License $7,150
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文 182ページになります。
商品コード:MAM190

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
インスリン製剤市場は今後も成長が続き、2020年には世界で391億ドル規模の市場に達することが予測されます。糖尿病患者数および糖尿病リスク人口の増加傾向、インスリンアナログ市場の拡大、医療費償還面での政策的支援などは同市場の促進要因といえるでしょう。一方、厳格な承認要件や高い製造コストの克服は課題に挙げることができます。
当レポートで対象とするインスリン製剤市場は、ヒトインスリン、インスリンアナログ等のインスリン製剤、およびインスリン送達デバイスを含みます。レポートでは2020年に至るインスリン製剤の世界市場予測(製剤、送達デバイス)、製剤タイプ別市場(インスリンアナログ、ヒトインスリン、作用時間別、速効型等)、主要製剤ブランド別市場(LANTUS、NOVORAPID、NOVOLOG、HUMALOG、ACTRAPID、MIXTARD、INSULATARD等)、送達デバイス別市場(ペン、ペンニードル、注射器)、対象疾患別市場(I型糖尿病、II型糖尿病)、主要国地域別市場など詳細に区分された市場予測と各種分析を掲載しています。また市場分析、競合状況、市場の主要企業などの調査情報も盛り込み、今後の市場展望と機会を検証していきます。

【レポート構成概要】MAM190_coverBrochure sub - Diabetes Care Devices Market (In BRIC)- Forecast to 2020.jpg
◆インスリン製剤の世界市場予測2013-2020年(US$)
・インスリン製剤
・送達デバイス市場

◆製剤タイプ別別市場予測と分析
(インスリンアナログとバイオシミラー)
・長時間作用型
・速効型
・予混合

(ヒトインスリン)
・短時間作用型
・中間型
・予混合

◆主要製剤ブランド別、市場予測と分析
インスリンアナログとバイオシミラー
・LANTUS
・NOVORAPID AND NOVOLOG
・HUMALOG
・その他ブランド

ヒトインスリン
・ACTRAPID, MIXTARD, AND INSULATARD
・HUMULIN
・INSUMAN

◆送達デバイス別、市場予測と分析
インスリンペン型注入器
・再利用型
・使い捨て型
インスリンペンニードル
・スタンダード
・セーフティタイプ
インスリン注射器

◆対象別、市場予測と分析
・I型糖尿病
・II型糖尿病

◆主要国地域別、市場予測と分析
北米
・米国
・カナダ
欧州
・ドイツ
・英国
・フランス
・その他欧州
アジア太平洋
・日本
・中国
・インド
・その他アジア太平洋
その他地域(Rest of the World)

◆市場分析、競合状況
・市場の促進要因と阻害要因、市場機会
・ポーターのファイブフォース分析(競合分析モデル)
・市場シェア
・競合シナリオ
・新製品、提携

◆リーディング企業動向
・B. BRAUN MELSUNGEN AG
・BECTON, DICKINSON AND COMPANY
・BIOCON LIMITED
・BIODEL INC.
・ELI LILLY AND COMPANY
・JULPHAR (ALSO KNOWN AS GULF PHARMACEUTICAL INDUSTRIES)
・NOVO NORDISK A/S
・SANOFI
・WOCKHARDT LIMITED
・YPSOMED AG
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020

Table of Contents

1 INTRODUCTION 17

1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED FOR THE STUDY 18
1.4 CURRENCY 19
1.5 LIMITATIONS 19
1.6 STAKEHOLDERS 19

2 RESEARCH METHODOLOGY 20

2.1 RESEARCH DATA 20
2.1.1 SECONDARY DATA 21
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY DATA 21
2.1.2.1 Key data from primary sources 22
2.1.2.2 Breakdown of primaries 22
2.2 MARKET SIZE ESTIMATION 23
2.2.1 BOTTOM-UP APPROACH 23
2.2.2 TOP-DOWN APPROACH 24
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 25
2.4 RESEARCH ASSUMPTIONS 26
2.4.1 ASSUMPTIONS 26

3 EXECUTIVE SUMMARY 27

3.1 INTRODUCTION 27
3.2 CURRENT MARKET SCENARIO 27
3.3 FUTURE OUTLOOK 28
3.4 CONCLUSION 31

4 PREMIUM INSIGHTS 32

4.1 GLOBAL HUMAN INSULIN MARKET (2015–2020) 32
4.2 GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY TYPE (2015) 33
4.3 GLOBAL HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY TYPE (2015-2020) 34
4.4 GLOBAL HUMAN INSULIN DRUGS MARKET, BY BRAND (2015 VS. 2020) 34
4.5 GLOBAL HUMAN INSULIN PRODUCTS MARKET SIZE, BY COUNTRY (2015-2020) 35

5 MARKET OVERVIEW 36

5.1 INTRODUCTION 37
5.2 MARKET SEGMENTATION 37
5.3 MARKET EVOLUTION 38
5.4 MARKET DYNAMICS 39
5.4.1 KEY MARKET DRIVERS 40
5.4.1.1 Growth in the number of diabetic patients 40
5.4.1.2 Rising market demand for human insulin analogs 41
5.4.1.3 Technological advancements in human insulin delivery devices 42
5.4.1.4 Favorable medical reimbursement scenario in developed countries 43
5.4.2 KEY MARKET RESTRAINTS 43
5.4.2.1 Stringent regulatory requirements for product approval 43
5.4.3 KEY MARKET OPPORTUNITIES 44
5.4.3.1 Expansion of healthcare infrastructure across Emerging markets 44
5.4.3.2 Expected patent expiry of key human insulin drugs 45
5.4.4 KEY MARKET CHALLENGE 45
5.4.4.1 High product manufacturing costs 45

6 INDUSTRY INSIGHTS 47

6.1 INTRODUCTION 48
6.2 INDUSTRY TRENDS 48
6.2.1 GROWING MARKET DEMAND FOR HUMAN INSULIN PENS 48
6.2.2 INCREASING MARKET FOCUS ON THE PIPELINE DEVELOPMENT OF NOVEL HUMAN INSULIN THERAPIES 49
6.3 PIPELINE ANALYSIS 51
6.3.1 BY COMPANY 51
6.3.2 BY CLINICAL TRIAL PHASE 52
6.3.3 PORTER’S FIVE FORCE ANALYSIS 53
6.3.3.1 Threat from new entrants 54
6.3.3.2 Threat from substitutes 54
6.3.3.3 Bargaining power of buyers 54
6.3.3.4 Bargaining power of suppliers 55
6.3.3.5 Intensity of competitive rivalry 55

7 GLOBAL HUMAN INSULIN MARKET, BY PRODUCT TYPE 56

7.1 INTRODUCTION 57
7.2 HUMAN INSULIN DRUGS 58
7.3 HUMAN INSULIN DELIVERY DEVICES 59

8 GLOBAL HUMAN INSULIN DRUGS MARKET, BY TYPE 61

8.1 INTRODUCTION 62
8.2 INSULIN ANALOGS AND BIOSIMILARS 62
8.2.1 LONG-ACTING 64
8.2.2 RAPID-ACTING 66
8.2.3 PREMIXED 67
8.3 HUMAN INSULIN BIOLOGICS 68
8.3.1 SHORT-ACTING 70
8.3.2 INTERMEDIATE-ACTING 71
8.3.3 PREMIXED 72

9 GLOBAL HUMAN INSULIN DRUGS MARKET, BY BRAND 73

9.1 INTRODUCTION 74
9.2 INSULIN ANALOGS AND BIOSIMILARS 75
9.2.1 LANTUS 77
9.2.2 NOVORAPID AND NOVOLOG 78
9.2.3 HUMALOG 79
9.2.4 OTHER BRANDS 80
9.3 HUMAN INSULIN BIOLOGICS 81
9.3.1 ACTRAPID, MIXTARD, AND INSULATARD 83
9.3.2 HUMULIN 84
9.3.3 INSUMAN 85

10 GLOBAL HUMAN INSULIN MARKET, BY DELIVERY DEVICE 86

10.1 INTRODUCTION 87
10.2 HUMAN INSULIN PENS 88
10.2.1 REUSABLE PENS 89
10.2.2 DISPOSABLE PENS 90
10.3 HUMAN INSULIN PEN NEEDLES 91
10.3.1 STANDARD PEN NEEDLES 92
10.3.2 SAFETY PEN NEEDLES 93
10.4 HUMAN INSULIN SYRINGES 94

11 GLOBAL HUMAN INSULIN MARKET, BY APPLICATION 95

11.1 INTRODUCTION 96
11.2 TYPE I DIABETES 96
11.3 TYPE II DIABETES 97

12 HUMAN INSULIN MARKET, BY REGION 98

12.1 INTRODUCTION 99
12.2 NORTH AMERICA 100
12.2.1 U.S. 103
12.2.2 CANADA 104
12.3 EUROPE 106
12.3.1 GERMANY 109
12.3.2 FRANCE 110
12.3.3 U.K. 112
12.3.4 REST OF EUROPE (ROE) 113
12.4 ASIA-PACIFIC (APAC) 115
12.4.1 JAPAN 118
12.4.2 CHINA 119
12.4.3 INDIA 120
12.4.4 REST OF ASIA-PACIFIC (ROAPAC) 122
12.5 REST OF THE WORLD (ROW) 124

13 COMPETITIVE LANDSCAPE 126

13.1 OVERVIEW 126
13.2 MARKET SHARE ANALYSIS 127
13.2.1 HUMAN INSULIN DRUGS MARKET 129
13.2.2 HUMAN INSULIN DELIVERY DEVICES MARKET 130
13.3 COMPETITIVE SCENARIO 131
13.4 RECENT DEVELOPMENTS 132
13.4.1 GEOGRAPHICAL EXPANSIONS 132
13.4.2 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 133
13.4.3 NEW PRODUCT LAUNCHES 134
13.4.4 AWARENESS PROGRAMS 136
13.4.5 FUNDING & SCHOLARSHIPS 137
13.4.6 STRATEGIC ACQUISITIONS 138

14 COMPANY PROFILES 139

(Overview, Financials, Products & Services, Strategy, & Developments)*
14.1 INTRODUCTION 139
14.2 B. BRAUN MELSUNGEN AG 143
14.3 BECTON, DICKINSON AND COMPANY 145
14.4 BIOCON LIMITED 148
14.5 BIODEL INC. 151
14.6 ELI LILLY AND COMPANY 152
14.7 JULPHAR (ALSO KNOWN AS GULF PHARMACEUTICAL INDUSTRIES) 158
14.8 NOVO NORDISK A/S 160
14.9 SANOFI 166
14.10 WOCKHARDT LIMITED 170
14.11 YPSOMED AG 172
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

15 APPENDIX 175

15.1 INSIGHTS OF INDUSTRY EXPERTS 175
15.2 DISCUSSION GUIDE 176
15.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 181
15.4 AVAILABLE CUSTOMIZATIONS 181
15.5 RELATED REPORTS 182

LIST OF TABLES

TABLE 1 KEY HUMAN INSULIN DRUGS: YEAR OF PATENT EXPIRY 38
TABLE 2 KEY HUMAN INSULIN THERAPIES UNDER PIPELINE DEVELOPMENT & COMMERCIALIZATION: 2005-2015 50
TABLE 3 HUMAN INSULIN PIPELINE: MAJOR COMPANIES INVOLVED 51
TABLE 4 HUMAN INSULIN PIPELINE: STAGES OF CLINICAL TRIAL 52
TABLE 5 GLOBAL HUMAN INSULIN MARKET SIZE, BY PRODUCT TYPE,
2013–2020 (USD MILLION) 57
TABLE 6 HUMAN INSULIN DRUGS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION) 59
TABLE 7 HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY REGION,
2013–2020 (USD MILLION) 60
TABLE 8 GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY TYPE,
2013–2020 (USD MILLION) 62
TABLE 9 GLOBAL INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY TYPE,
2013–2020 (USD MILLION) 63
TABLE 10 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY REGION,
2013–2020 (USD MILLION) 64
TABLE 11 LONG-ACTING INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE,
BY REGION, 2013–2020 (USD MILLION) 65
TABLE 12 RAPID-ACTING INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE,
BY REGION, 2013–2020 (USD MILLION) 66
TABLE 13 PREMIXED INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE,
BY REGION, 2013–2020 (USD MILLION) 67
TABLE 14 GLOBAL HUMAN INSULIN BIOLOGICS MARKET SIZE, BY TYPE,
2013–2020 (USD MILLION) 68
TABLE 15 HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION,
2013–2020 (USD MILLION) 69
TABLE 16 SHORT-ACTING HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION,
2013–2020 (USD MILLION) 70
TABLE 17 INTERMEDIATE-ACTING HUMAN INSULIN BIOLOGICS MARKET SIZE,
BY REGION, 2013–2020 (USD MILLION) 71
TABLE 18 PREMIXED HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION,
2013–2020 (USD MILLION) 72
TABLE 19 GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT TYPE,
2013–2020 (USD MILLION) 74
TABLE 20 GLOBAL INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY BRAND,
2013–2020 (USD MILLION) 75
TABLE 21 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY REGION,
2013–2020 (USD MILLION) 76
TABLE 22 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR LANTUS,
BY REGION, 2013–2020 (USD MILLION) 77
TABLE 23 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR NOVORAPID AND NOVOLOG, BY REGION, 2013–2020 (USD MILLION) 78
TABLE 24 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR HUMALOG,
BY REGION, 2013–2020 (USD MILLION) 80
TABLE 25 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR OTHER BRANDS,
BY REGION, 2013–2020 (USD MILLION) 81
TABLE 26 GLOBAL HUMAN INSULIN BIOLOGICS MARKET SIZE, BY BRAND,
2013–2020 (USD MILLION) 81
TABLE 27 HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION,
2013–2020 (USD MILLION) 82
TABLE 28 HUMAN INSULIN BIOLOGICS MARKET SIZE FOR ACTRAPID, MIXTARD, AND INSULATARD, BY REGION, 2013–2020 (USD MILLION) 83
TABLE 29 HUMAN INSULIN BIOLOGICS MARKET SIZE FOR HUMULIN, BY REGION,
2013–2020 (USD MILLION) 84
TABLE 30 HUMAN INSULIN BIOLOGICS MARKET SIZE FOR INSUMAN, BY REGION,
2013–2020 (USD MILLION) 85
TABLE 31 GLOBAL HUMAN INSULIN MARKET SIZE, BY DELIVERY DEVICE,
2013–2020 (USD MILLION) 87
TABLE 32 GLOBAL HUMAN INSULIN PENS MARKET SIZE, BY PRODUCT TYPE,
2013–2020 (USD MILLION) 88
TABLE 33 HUMAN INSULIN PENS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION) 88
TABLE 34 REUSABLE HUMAN INSULIN PENS MARKET SIZE, BY REGION,
2013–2020 (USD MILLION) 89
TABLE 35 DISPOSABLE HUMAN INSULIN PENS MARKET SIZE, BY REGION,
2013–2020 (USD MILLION) 90
TABLE 36 GLOBAL HUMAN INSULIN PEN NEEDLES MARKET SIZE, BY PRODUCT TYPE,
2013–2020 (USD MILLION) 91
TABLE 37 HUMAN INSULIN PEN NEEDLES MARKET SIZE, BY REGION,
2013–2020 (USD MILLION) 92
TABLE 38 HUMAN INSULIN STANDARD PEN NEEDLES MARKET SIZE, BY REGION,
2013–2020 (USD MILLION) 93
TABLE 39 HUMAN INSULIN SAFETY PEN NEEDLES MARKET SIZE, BY REGION,
2013–2020 (USD MILLION) 94
TABLE 40 HUMAN INSULIN SYRINGES MARKET SIZE, BY REGION,
2013–2020 (USD MILLION) 94
TABLE 41 HUMAN INSULIN MARKET SIZE, BY REGION, 2013–2020 (USD MILLION) 99
TABLE 42 NORTH AMERICA: HUMAN INSULIN MARKET SIZE, BY COUNTRY,
2013–2020 (USD MILLION) 100
TABLE 43 NORTH AMERICA: HUMAN INSULIN MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 100
TABLE 44 NORTH AMERICA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 101
TABLE 45 NORTH AMERICA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE,
BY PRODUCT, 2013–2020 (USD MILLION) 101
TABLE 46 U.S.: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 103
TABLE 47 U.S.: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 104
TABLE 48 U.S.: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 104
TABLE 49 CANADA: HUMAN INSULIN MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 105
TABLE 50 CANADA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 105
TABLE 51 CANADA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 105
TABLE 52 EUROPE: HUMAN INSULIN MARKET SIZE, BY COUNTRY,
2013–2020 (USD MILLION) 106
TABLE 53 EUROPE: HUMAN INSULIN MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 106
TABLE 54 EUROPE: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 107
TABLE 55 EUROPE: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 107
TABLE 56 GERMANY: HUMAN INSULIN MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 109
TABLE 57 GERMANY: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 109
TABLE 58 GERMANY: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE,
BY PRODUCT, 2013–2020 (USD MILLION) 110
TABLE 59 FRANCE: HUMAN INSULIN MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 110
TABLE 60 FRANCE: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 111
TABLE 61 FRANCE: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 111
TABLE 62 U.K.: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 112
TABLE 63 U.K.: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 112
TABLE 64 U.K.: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 113
TABLE 65 ROE: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 113
TABLE 66 ROE: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 114
TABLE 67 ROE: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 114
TABLE 68 APAC: HUMAN INSULIN MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION) 115
TABLE 69 APAC: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 115
TABLE 70 APAC: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 116
TABLE 71 APAC: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 116
TABLE 72 JAPAN: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 118
TABLE 73 JAPAN: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 118
TABLE 74 JAPAN: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 119
TABLE 75 CHINA: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 119
TABLE 76 CHINA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 120
TABLE 77 CHINA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 120
TABLE 78 INDIA: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 121
TABLE 79 INDIA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 121
TABLE 80 INDIA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 121
TABLE 81 ROAPAC: HUMAN INSULIN MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 122
TABLE 82 ROAPAC: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 123
TABLE 83 ROAPAC: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 123
TABLE 84 ROW: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 124
TABLE 85 ROW: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 125
TABLE 86 ROW: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,
2013–2020 (USD MILLION) 125
TABLE 87 GEOGRAPHICAL EXPANSIONS, 2012–2015 132
TABLE 88 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2012–2015 133
TABLE 89 NEW PRODUCT LAUNCHES AND PRODUCT APPROVALS, 2012–2015 134
TABLE 90 AWARENESS PROGRAMS, 2012–2015 136
TABLE 91 FUNDING & SCHOLARSHIPS, 2012–2015 137
TABLE 92 STRATEGIC ACQUISITIONS, 2012–2015 138

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 20
FIGURE 2 BOTTOM-UP APPROACH 23
FIGURE 3 TOP-DOWN APPROACH 24
FIGURE 4 DATA TRIANGULATION 25
FIGURE 5 ASSUMPTIONS FOR THE RESEARCH STUDY 26
FIGURE 6 HUMAN INSULIN MARKET SHARE, BY KEY PLAYER, 2014 27
FIGURE 7 FUTURE TRENDS: HUMAN INSULIN MARKET SIZE, BY PRODUCT (2015–2020) 28
FIGURE 8 FUTURE TRENDS: HUMAN INSULIN DRUGS MARKET SHARE, BY TYPE (2015 VS. 2020) 29
FIGURE 9 FUTURE TRENDS: HUMAN INSULIN DRUGS MARKET SIZE, BY BRAND (2015–2020) 29
FIGURE 10 FUTURE TRENDS: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE (2015–2020) 30
FIGURE 11 FUTURE TRENDS: HUMAN INSULIN MARKET SHARE, BY REGION (2015) 31
FIGURE 12 ATTRACTIVE GROWTH OPPORTUNITIES IN THE HUMAN INSULIN MARKET 32
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE HUMAN INSULIN MARKET
IN 2015 33
FIGURE 14 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF ALL SEGMENTS OF THE HUMAN INSULIN DELIVERY DEVICES MARKET IN 2015 34
FIGURE 15 LANTUS IS EXPECTED TO BE THE LEADING INSULIN ANALOG TILL 2020 34
FIGURE 16 CHINA AND INDIA TO LEAD THE MARKET DEMAND FOR HUMAN INSULIN PRODUCTS DURING THE FORECAST PERIOD 35
FIGURE 17 MARKET EVOLUTION OF HUMAN INSULIN PRODUCTS 38
FIGURE 18 HUMAN INSULIN MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES 39
FIGURE 19 GROWTH IN DIABETIC PATIENT POPULATION ACROSS KEY WHO REGIONS
(2000–2030) 40
FIGURE 20 PROPORTION OF GERIATRIC POPULATION, BY COUNTRY (2012 VS. 2020) 41
FIGURE 21 GLOBAL TREND IN GOVERNMENT HEALTHCARE EXPENDITURE: DEVELOPED VS. DEVELOPING COUNTRIES (2010–2012) 44
FIGURE 22 PORTER’S FIVE FORCES ANALYSIS (2014): INCREASING NUMBER OF NEW PRODUCT MANUFACTURERS INCREASES MARKET COMPETITION 53
FIGURE 23 DELIVERY DEVICES POISED TO GROW AT THE HIGHEST RATE DURING 2015-2020 57
FIGURE 24 U.S. & EUROPE LEAD GLOBALLY, IN TERMS OF THE NUMBER OF ONGOING HUMAN INSULIN-BASED CLINICAL STUDIES (2015) 58
FIGURE 25 LONG-ACTING DRUGS TO LEAD THE INSULIN ANALOGS AND BIOSIMILARS MARKET TILL 2020 63
FIGURE 26 ASIA-PACIFIC IS POISED TO BE THE FASTEST GROWING MARKET FOR LONG-ACTING INSULIN ANALOGS AND BIOSIMILAR PRODUCTS DURING FORECAST PERIOD 65
FIGURE 27 INTERMEDIATE-ACTING DRUGS WILL CONTINUE TO DOMINATE THE HUMAN INSULIN BIOLOGICS MARKET TILL 2020 69
FIGURE 28 NORTH AMERICA IS EXPECTED TO DOMINATE THE INTERMEDIATE-ACTING HUMAN INSULIN BIOLOGICS MARKET DURING THE STUDY PERIOD 71
FIGURE 29 INSULIN ANALOGS & BIOSIMILAR DRUGS POISED TO GROW AT THE FASTEST RATE 75
FIGURE 30 LANTUS EXPECTED TO HOLD THE LARGEST SHARE OF INSULIN ANALOGS & BIOSIMILAR BRANDS MARKET TILL 2020 76
FIGURE 31 ASIA-PACIFIC POISED TO BE THE FASTEST-GROWING MARKET FOR NOVORAPID DURING THE FORECAST PERIOD 79
FIGURE 32 HUMULIN IS POISED TO BE THE FASTEST-GROWING HUMAN INSULIN BIOLOGICS BRANDS DURING 2015-2020 82
FIGURE 33 INSULIN PENS TO DOMINATE THE HUMAN INSULIN DELIVERY DEVICES MARKET DURING THE FORECAST PERIOD (2015–2020) 87
FIGURE 34 APAC TO DOMINATE THE HUMAN INSULIN PEN NEEDLES MARKET BY 2020 91
FIGURE 35 INDIA WILL HAVE THE HIGHEST DIABETES POPULATION BY 2030 97
FIGURE 36 MARKET TRENDS: NORTH AMERICAN HUMAN INSULIN MARKET (2015-2020) 102
FIGURE 37 MARKET TRENDS: EUROPEAN HUMAN INSULIN MARKET (2015-2020) 108
FIGURE 38 ASIA-PACIFIC HUMAN INSULIN MARKET SNAPSHOT, 2015-2020 117
FIGURE 39 LEADING PLAYERS ADOPTED THE STRATEGY OF GEOGRAPHIC EXPANSIONS TO STRENGTHEN THEIR MARKET POSITIONING DURING 2012 TO 2015 126
FIGURE 40 GLOBAL HUMAN INSULIN MARKET SHARE, BY KEY PLAYER (2014) 127
FIGURE 41 GLOBAL HUMAN INSULIN DRUGS MARKET RANKING, BY KEY PLAYER (2014) 129
FIGURE 42 GLOBAL HUMAN INSULIN DELIVERY DEVICES MARKET RANKING, BY KEY PLAYER (2014) 130
FIGURE 43 CONTINUOUS GEOGRAPHIC EXPANSION IS STIMULATING MARKET COMPETITION FOR CAPACITY BUILDING AMONG KEY PLAYERS 131
FIGURE 44 GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS* (2014) 139
FIGURE 45 LEADING COMPANIES ARE FOCUSING ON CAPACITY BUILDING TO STRENGTHEN THEIR PRODUCT DEVELOPMENT & MANUFACTURING BASE 141
FIGURE 46 LEADING HUMAN INSULIN MANUFACTURERS ARE FOCUSING ON PRODUCT COMMERCIALIZATION TO STRENGTHEN THEIR MARKET POSITION 142
FIGURE 47 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT 143
FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 145
FIGURE 49 BIOCON LIMITED: COMPANY SNAPSHOT 148
FIGURE 50 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 152
FIGURE 51 JULPHAR: COMPANY SNAPSHOT 158
FIGURE 52 NOVO NORDISK A/S: COMPANY SNAPSHOT 160
FIGURE 53 SANOFI: COMPANY SNAPSHOT 166
FIGURE 54 WOCKHARDT LIMITED: COMPANY SNAPSHOT 170
FIGURE 55 YPSOMED AG: COMPANY SNAPSHOT 172

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。